Business
Medicenna Therapeutics Corp. Opens the Market
Medicenna Therapeutics Corp. Opens the Market Canada NewsWire TORONTO, May 25, 2...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Therapeutics Corp. Opens the Market\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, May 25, 2017\n\n\n\nTORONTO, May 25, 2017 /CNW/ - Fahar Merchant, PhD, Co-Founder, Chairman, President and CEO, Medicenna Therapeutics Corp. (MDNA), joined Tim Babcock, Director, Listed Issuer Services, TSX Venture Exchange, to open the market. Medicenna is a clinical stage immuno-oncology company that is developing therapeutics for the treatment of central nervous system cancers. Medicenna Therapeutics Corp. commenced trading on the TSX Venture Exchange on March 3, 2017.\n\n \n \n\n \n\n\n\n\nSOURCE TMX Group Limited\n\n\n\nView original content with multimedia: http://www.newswire.ca/en/releases/archive/May2017/25/c3076.html\n\n\n\n\nCopyright CNW Group 2017","length":3033,"tagName":"div"}]